G133
GR 89696 fumarate salt
solid
동의어(들):
4-[(3,4-Dichlorophenyl)acetyl]-3-(1-pyrrolidinylmethyl)-1-piperazinecarboxylic acid methyl ester fumarate salt
로그인조직 및 계약 가격 보기
모든 사진(2)
About This Item
실험식(Hill 표기법):
C19H25Cl2N3O3 · C4H4O4
CAS Number:
Molecular Weight:
530.40
MDL number:
UNSPSC 코드:
12352200
PubChem Substance ID:
NACRES:
NA.77
추천 제품
양식
solid
Quality Level
색상
off-white
solubility
ethanol: 4.0 mg/mL
DMSO: >50 mg/mL
H2O: 8.5 mg/mL
SMILES string
OC(=O)\C=C\C(O)=O.COC(=O)N1CCN(C(CN2CCCC2)C1)C(=O)Cc3ccc(Cl)c(Cl)c3
InChI
1S/C19H25Cl2N3O3.C4H4O4/c1-27-19(26)23-8-9-24(15(13-23)12-22-6-2-3-7-22)18(25)11-14-4-5-16(20)17(21)10-14;5-3(6)1-2-4(7)8/h4-5,10,15H,2-3,6-9,11-13H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
InChI key
ABTNETSDXZBJTE-WLHGVMLRSA-N
유전자 정보
human ... OPRK1(4986)
애플리케이션
GR 89696 fumarate salt has been used as a κ κ2 opioid receptor (KOR) agonist to study its anti-scratching and antipruritic effects on monkeys.
생화학적/생리학적 작용
GR 89696 fumarate is a selective κ2 opioid receptor agonist.
법적 정보
Sold for research purposes under agreement from GlaxoSmithKline
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
개인 보호 장비
Eyeshields, Gloves, type N95 (US)
가장 최신 버전 중 하나를 선택하세요:
Bent W Schoultz et al.
European journal of nuclear medicine and molecular imaging, 37(6), 1174-1180 (2010-02-17)
The recent development in radiosynthesis of the (11)C-carbamate function increases the potential of [(11)C]GR103545, which for the last decade has been regarded as promising for imaging the kappa-opioid receptor (kappa-OR) with PET. In the present study, [(11)C]GR103545 was evaluated in
P J Birch et al.
British journal of pharmacology, 103(3), 1819-1823 (1991-07-01)
1. The effect of a novel, highly potent and selective kappa-opioid receptor agonist, GR89696, has been evaluated in two animal models of cerebral ischaemia: transient bilateral carotid artery occlusion in the Mongolian gerbil and permanent, unilateral middle cerebral artery occlusion
J F Herrero et al.
British journal of pharmacology, 110(1), 303-309 (1993-09-01)
1. The evidence for kappa-receptor heterogeneity is equivocal. We have now investigated this question by comparing the effects of five putatively selective kappa-agonists. The parameters examined were: the relative potencies in depressing hindlimb flexor muscle reflexes to noxious pinch stimuli
H Rogers et al.
British journal of pharmacology, 106(4), 783-789 (1992-08-01)
1. The pharmacological profile of GR94839, a kappa-opioid agonist with limited access to the central nervous system, has been investigated. Its antinociceptive activity has been compared with that of GR103545, a centrally-penetrating kappa-agonist and ICI204448, the previously described peripherally-selective kappa-agonist.
Woong Mo Kim et al.
Anesthesia and analgesia, 113(4), 934-940 (2011-07-27)
Although bone cancer-related pain is one of the most disruptive symptoms in patients with advanced cancer, patients are often refractory to pharmacological treatments; thus, more effective treatments for bone cancer pain are needed. We evaluated the analgesic efficacy of and
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.